Entera Bio Ltd. (NASDAQ:ENTX) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Entera Bio, with four buy ratings and one sell rating; the average 12-month price target is $9.00.
• Renaissance Technologies increased its Entera Bio holdings by 338.4% in the first quarter, while institutional investors collectively own 14.11% of the company.
• Entera Bio shares recently traded at $2.80, within a 12-month range of $0.91 to $4.20. The company reported a quarterly loss of $0.14 per share, missing the consensus estimate of a $0.08 loss.

Shares of Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $9.00.

ENTX has been the subject of a number of recent research reports. HC Wainwright reiterated a "buy" rating on shares of Entera Bio in a report on Wednesday, June 24th. Guggenheim initiated coverage on shares of Entera Bio in a research note on Thursday. They set a "buy" rating for the company. Wall Street Zen upgraded shares of Entera Bio to a "sell" rating in a research note on Saturday, August 8th. Cantor Fitzgerald initiated coverage on shares of Entera Bio in a report on Tuesday. They issued an "overweight" rating on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Entera Bio in a research report on Friday, July 17th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Entera Bio stock. Renaissance Technologies LLC raised its holdings in Entera Bio Ltd. (NASDAQ:ENTX - Free Report) by 338.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 473,442 shares of the company's stock after buying an additional 365,441 shares during the quarter. Renaissance Technologies LLC owned about 0.96% of Entera Bio worth $526,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.11% of the company's stock.

Entera Bio Price Performance

NASDAQ ENTX traded down $0.01 during trading on Thursday, reaching $2.80. 233,799 shares of the company's stock traded hands, compared to its average volume of 1,036,109. The firm has a market cap of $486.72 million, a price-to-earnings ratio of -8.00 and a beta of 1.38. The company's 50 day simple moving average is $2.87 and its two-hundred day simple moving average is $1.85. Entera Bio has a 12-month low of $0.91 and a 12-month high of $4.20.

Entera Bio (NASDAQ:ENTX - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06).

About Entera Bio

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company's proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio's lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.